There are various errors contained in the references 6, 7, 8, 9, 10, 25, 28, 29, 39, 40 and 43. A summary of issues is as follows: * References 6 - 10 contain incorrect information and numbering. They should read as follows: 6. (1998) Control and surveillance of African trypanosomiasis. Report of a WHO Expert Committee. World Health Organ Tech Rep Ser 881: I-VI, 1-114. 7. Chappuis F, Udayraj N, Stietenroth K, Meussen A, Bovier PA (2005) Eflornithine is safer than melarsoprol for the treatment of second-stage Trypanosoma brucei gambiense human African trypanosomiasis. Clin Infect Dis 41: 748-751. 8. Kennedy PG (2008) The continuing problem of human African trypanosomiasis (sleeping sickness). Ann Neurol 64: 116-126. 9. Pepin J, Milord F (1994) The treatment of human African trypanosomiasis. Adv Parasitol 33: 1-47. 10. Schmid C, Richer M, Bilenge CM, Josenando T, Chappuis F, et al. (2005) Effectiveness of a 10-day melarsoprol schedule for the treatment of late-stage human African trypanosomiasis: confirmation from a multinational study (IMPAMEL II). J Infect Dis 191: 1922-1931. * Reference 25, 28 and 29 should be removed. * Reference 39 is incorrect and should read as follows: Lipinski CA (2004) Lead- and drug-like compounds: the rule-of-five revolution. Drug Discov Today: Technologies 4: 337-341. * Reference 40 is incorrect and should read as follows: Wager T, Verhoest P, Villalobos A (2010) Moving beyond Rules: The Development of a Central Nervous System Multiparameter Optimization (CNS MPO) Approach To Enable Alignment of Druglike Properties. ACS Chem Neurosci 1. * Reference 43 is incorrect and should read as follows: Sykes ML, Avery VM (2009) A luciferase based viability assay for ATP detection in 384-well format for high throughput whole cell screening of Trypanosoma brucei brucei bloodstream form strain 427. Parasit Vectors 2: 54.
Citation: Sykes ML, Baell JB, Kaiser M, Chatelain E, Moawad SR, Ganame D, et al. (2013) Correction: Identification of Compounds with Anti-Proliferative Activity against Trypanosoma brucei brucei Strain 427 by a Whole Cell Viability Based HTS Campaign. PLoS Negl Trop Dis 7(1): 10.1371/annotation/cc952155-c929-4e4f-8fc0-43cb84c50452. doi:10.1371/annotation/cc952155-c929-4e4f-8fc0-43cb84c50452
Published: January 22, 2013
Copyright: © 2013 . This is an open-access article distributed under the terms of the Creative Commons Attribution License, which permits unrestricted use, distribution, and reproduction in any medium, provided the original author and source are credited.
Competing interests: No competing interests declared.